J 2019

Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Retrospective Study by the EBMT Chronic Malignancies Working Party

RADUJKOVIC, Aleksandar, Sascha DIETRICH, Henric-Jan BLOK, Arnon NAGLER, Francis AYUK et. al.

Basic information

Original name

Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Retrospective Study by the EBMT Chronic Malignancies Working Party

Authors

RADUJKOVIC, Aleksandar (276 Germany, guarantor), Sascha DIETRICH (276 Germany), Henric-Jan BLOK (528 Netherlands), Arnon NAGLER (376 Israel), Francis AYUK (276 Germany), Juergen FINKE (276 Germany), Johanna TISCHER (276 Germany), Jiří MAYER (203 Czech Republic, belonging to the institution), Yener KOC (792 Turkey), Federica SORA (380 Italy), Jakob PASSWEG (756 Switzerland), Jenny L. BYRNE (826 United Kingdom of Great Britain and Northern Ireland), Pavel JINDRA (203 Czech Republic), Joan Hendrik VEELKEN (528 Netherlands), Gerard SOCIE (250 France), Johan MAERTENS (56 Belgium), Nicolaas SCHAAP (528 Netherlands), Michael STADLER (276 Germany), Maija ITALA-REMES (246 Finland), Eleni THOLOULI (826 United Kingdom of Great Britain and Northern Ireland), Mutlu ARAT (792 Turkey), Vanderson ROCHA (76 Brazil), Per LJUNGMAN (752 Sweden), Ibrahim YAKOUB-AGHA (250 France), Nicolaus KROGER (276 Germany) and Yves CHALANDON (756 Switzerland)

Edition

Biology of Blood and Marrow Transplantation, New York, Elsevier Science INC, 2019, 1083-8791

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 3.853

RIV identification code

RIV/00216224:14110/19:00112124

Organization unit

Faculty of Medicine

DOI

UT WoS

000492801700013

Keywords in English

Chronic myeloid leukemia; Allogeneic stem cell; transplantation; Outcome; Blast crisis; Tyrosine kinase inhibitor

Tags

Tags

International impact, Reviewed
Změněno: 11/3/2020 14:14, Mgr. Tereza Miškechová

Abstract

V originále

The prognosis of patients with blast crisis (BC) chronic myeloid leukemia (CML) is still dismal. Allogeneic stem cell transplantation represents the only curative treatment option, but data on transplant outcomes are scarce. We therefore conducted a retrospective, registry-based study of adult patients allografted for BC CML, focusing on patients with active disease at transplant and pretransplant prognostic factors. One hundred seventy patients allografted for BC CML after tyrosine kinase inhibitor pretreatment between 2004 and 2016 were analyzed. Before transplant, 95 patients were in remission, whereas 75 patients had active BC. In multivariable analysis of the entire cohort, active BC at transplant was the strongest factor associated with decreased overall survival (hazrd ratio, 1.87; P = .010) and shorter leukemia-free survival (LFS; hazard ratio, 1.69; P= .017). For patients with BC in remission at transplant, advanced age (>= 45 years), lower performance status (<= 80%), longer interval from diagnosis BC to transplant (>12 months), myeloablative conditioning, and unrelated donor (UD) transplant were risk factors for inferior survival. In patients with active BC, only UD transplant was significantly associated with prolonged LFS and trended toward improved overall survival. In summary, survival of patients allografted for BC CML was strongly dependent on pretransplant remission status. In patients with remission of BC, conventional prognostic factors remained the major determinants of outcome, whereas in those with active BC at transplant, UD transplant was associated with prolonged LFS in our study. (C) 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.